Ondansetron (Zofran) precautions. - Free Online Library

No changes were recommended in oral

dosages. The most common uses are for

chemotherapy-induced and post-operative nausea.

Zofran is a commonly used medication for both children and adults

for the treatment of http://www.medicinenet.com/ondansetron-oral/article.htm nausea. Retrieved from http://www.fda.gov/

Drugs/DrugSafety ucm310190.htm

Wallace J. Electrolyte

abnormalities, particularly hypokalemia and hypomagnesemia should be

corrected prior to administration of Zofran.

Nurse practitioners or others prescribing or administering this

medication need to be aware of these changes.


U.S. Food and Drug Administration. Instead, the current

recommendation is for 0.15 mg/kg every four hours for three doses with

no single dose to exceed 16 Zofran lawsuit mg. (2011). Due to incidents of

prolongation of the QT interval of the ECG following Zofran

administration, the manufacturer, GlaxoSmithKline, was required by the

FDA to conduct a study to assess this particular risk. Prolongation of

the QT interval predisposes the patient to development of a potentially

lethal ventricular tachycardia known as Torsades de Pointes.

As a result of that study, dosage recommendations for the

intravenous form of the medication has been changed. Henkelman, EdD, MSN, RN

Touro University Nevada

COPYRIGHT 2013 Nevada Nurses Association

No portion of this article can be reproduced without the express written permission from the copyright holder.

Copyright 2013 Gale, Cengage Learning. All rights reserved.

. FDA drug safety

communication: New information regarding QT prolongation with

ondansetron (Zofran). Lower dosages used in the treatment of post-operative nausea

are also unchanged.

In addition to the dosage change, caution is recommended in

administration of Zofran to patients with congenital long QT intervals,

patients with congestive heart failure, those with bradyarrhythmias, or

those taking other medications which prolong QT intervals. The previous 32 mg,

single intravenous dose should now be avoided